The company provides project management, engineering, and planning consultancy services for large-scale infrastructure projects, primarily focusing on highways, bridges, and urban development for government agencies.
The business lacks a durable moat as evidenced by low average ROE and ROCE that barely cover the cost of capital. While they possess technical certifications required for government bidding, the fragmented nature of the consultancy market and negative cash conversion indicate a lack of pricing power and high competition.
Capital has been primarily utilized for working capital and maintaining operations, with a recent proposal to spend up to 31 Crores on purchasing office premises from promoters, which raises questions about the efficiency of capital use versus shareholder returns.
The investment collapsed as the reported earnings proved to be a mirage, never translating into actual cash for shareholders. The management prioritized their own interests by siphoning 31 Crores of company capital into their own pockets through a property purchase, effectively hollowing out the balance sheet. As unbilled revenues and receivables continued to balloon without collection, the company faced a liquidity crunch, leaving investors holding a shell of a consultancy with no tangible assets and a leadership team that had already extracted the value.
RichFakir rates Artefact Projects Ltd's business quality as poor — 27/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Artefact Projects Ltd is trading about 35% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Artefact Projects Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Artefact Projects Ltd's fair value is about ₹70 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →